Nasofan Aqueous (Fluticasone Propionate)

Fluticasone propionate, the active ingredient in Nasofan Aqueous, is a corticosteroid presented as a nasal spray for nasal administration. It reduces inflammation of the nasal mucosa and is indicated for the treatment of allergic rhinitis and associated nasal congestion in patients who require topical anti‑inflammatory therapy.

GNH USA supplies Nasofan Aqueous as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide, providing reliable sourcing for bulk and individual orders across multiple markets.

Nasofan Aqueous, a corticosteroid nasal spray, is employed to manage inflammatory conditions of the nasal passages.

- Allergic rhinitis: alleviates sneezing, itching, rhinorrhea and nasal obstruction. - Seasonal allergic rhinitis: provides symptom relief during pollen or allergen exposure periods. - Nasal congestion due to allergic rhinitis: decreases mucosal edema and improves airflow.

Nasofan Aqueous may cause local and systemic adverse reactions.

Common Side Effects: - Nasal irritation or burning sensation - Epistaxis (nosebleeds) - Headache - Throat irritation or dryness

Serious or Rare Side Effects: - Nasal septal perforation - Adrenal suppression with prolonged high‑dose use - Cataracts or glaucoma - Severe allergic reaction such as anaphylaxis

Before using Nasofan Aqueous, consider the following precautions.

- Hypersensitivity: avoid if the patient has known allergy to fluticasone or other corticosteroids. - Recent nasal surgery or trauma: use with caution to prevent impaired healing. - Prolonged high‑dose therapy: monitor for signs of adrenal suppression. - Ocular pressure: assess patients with glaucoma or a history of cataracts. - Live intranasal vaccines: do not administer concurrently. - Store at room temperature: keep in the original container, protect from moisture and heat.

Fluticasone propionate can interact with other medicines.

Major Interactions (Avoid): - Strong CYP3A4 inhibitors (e.g., ketoconazole, itraconazole) – may increase systemic exposure. - Systemic corticosteroids – additive glucocorticoid effects. - Ritonavir – can raise fluticasone levels.

Moderate Interactions (Monitor Closely): - Moderate CYP3A4 inhibitors (e.g., erythromycin) – may modestly increase exposure. - Nasal decongestants (e.g., oxymetazoline) – may increase local irritation.